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Abstract
 
Acute graft-versus-host disease (aGVHD) is still a major obstacle in clinical allogeneic bone
marrow (BM) transplantation. CD4
 
 
 
CD25
 
  
 
regulatory T (T
 
reg
 
) cells have recently been shown
to suppress proliferative responses of CD4
 
 
 
CD25
 
  
 
T cells to alloantigenic stimulation in vitro
and are required for ex vivo tolerization of donor T cells, which results in their reduced poten-
tial to induce aGVHD. Here we show that CD4
 
 
 
CD25
 
  
 
T cells isolated from the spleen or
BM of donor C57BL/6 (H-2
 
b
 
) mice that have not been tolerized are still potent inhibitors of
the alloresponse in vitro and of lethal aGVHD induced by C57BL/6 CD4
 
 
 
CD25
 
  
 
T cells in
irradiated BALB/c (H-2
 
d
 
) hosts in vivo. The addition of the CD4
 
 
 
CD25
 
  
 
T
 
reg 
 
cells at a 1:1 ra-
tio with responder/inducer CD4
 
 
 
CD25
 
  
 
T cells resulted in a 
 
 
 
90% inhibition of the mixed
leukocyte reaction and marked protection from lethal GVHD. This protective effect depended
in part on the ability of the transferred CD4
 
 
 
CD25
 
  
 
T cells to secrete interleukin 10 and
occurred if the T
 
reg 
 
cells were of donor, but not host, origin. Our results demonstrate that the
balance of donor-type CD4
 
 
 
CD25
 
  
 
T
 
reg 
 
and conventional CD4
 
 
 
CD25
 
  
 
T cells can determine
the outcome of aGVHD.
Key words: immune regulation • T lymphocytes • IL-10 • mixed leukocyte reaction • 
alloimmunity
 
Introduction
 
GVHD remains a major complication after allogeneic bone
marrow transplantation (BMT),
 
* 
 
thereby preventing the
widespread use of this therapeutic approach for the treat-
ment of malignant and nonmalignant diseases (1, 2). Acute
GVHD (aGVHD) is initiated by alloreactive donor T cells
that recognize MHC class I and II molecules on the surface
of host cells as well as peptides presented by them. The in-
filtration of several target organs such as gut, liver, and skin
by donor leukocytes including T cells is thought to be one
of the key processes in the early phase of aGVHD (3). The
activation and expansion of the donor T cells, leading to
the secretion of proinflammatory cytokines and the recruit-
ment of additional inflammatory effector cells to these sites,
further damages the affected tissues (4–6).
The most effective means to avoid GVHD is T cell de-
pletion of the bone marrow (BM) graft (7, 8). However,
such a pretreatment of the donor inoculum has been shown
in numerous studies to be associated with a higher inci-
dence of graft failure and a higher risk for opportunistic in-
fections, tumor relapse, and secondary lymphoproliferative
diseases (9–11). Therefore, recent approaches have aimed at
the induction of alloantigen-specific immune tolerance of
the donor T cell population before transplantation (12, 13).
Recently, CD4
 
 
 
CD25
 
  
 
T cells with immunoregulatory
potential have been isolated from the thymus and periphery
of mice, rats, and humans, and have been shown to share
similar characteristics and functions (14–16). They have
been shown in various mouse models to prevent the devel-
opment of experimental autoimmune diseases such as dia-
betes and inflammatory bowel disease (17–20), and regulate
the homeostatic proliferation of the peripheral T cell pool
(21). In vitro they suppress the activation and proliferation
of cocultured conventional CD4
 
  
 
and CD8
 
  
 
T cells in re-
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sponse to polyclonal stimuli in a direct, cell contact–depen-
dent way by inhibiting their IL-2 production (22–24).
Although stimulation via their TCR appears to be a pre-
requisite for the suppressor function of CD4
 
 
 
CD25
 
  
 
T
cells, the exact mechanism of suppression is still unknown
(25). Several groups have demonstrated that CD4
 
 
 
CD25
 
 
 
T cells secrete the immunosuppressive cytokine IL-10
upon activation in vitro (26, 27). However, blocking IL-10
did not abrogate suppression in vitro in proliferation assays
(22, 28, 29). In vivo, IL-10 production by CD4
 
 
 
CD25
 
  
 
T
cells seemed to be essential in some (30, 31), but not in
other, systems (32). Another cytokine implicated in the
suppressor function of CD4
 
 
 
CD25
 
  
 
T cells is TGF-
 
  
 
(26,
30, 33) and in particular, surface-bound TGF-
 
 
 
 (26). Fi-
nally, it has been controversial whether and how the high
expression levels of CTL-associated antigen (CTLA)-4 on
CD4
 
 
 
CD25
 
  
 
T cells are related to their suppressor func-
tion (24, 34, 35).
Human CD4
 
 
 
CD25
 
  
 
regulatory T (T
 
reg
 
) cells isolated
from peripheral blood (PB) have been shown to suppress
alloresponses in the MLR (27, 36), and two previous re-
ports have indicated a role for murine CD4
 
 
 
CD25
 
  
 
T cells
in tolerance induction to alloantigens. Taylor et al. (37)
showed in an allogeneic BMT model that the depletion of
CD25
 
  
 
cells from the donor CD4
 
  
 
T cell population com-
pletely abrogated ex vivo tolerization to host alloantigens
and resulted in a loss of protection against GVHD. Kingsley
et al. (31) demonstrated that the pretreatment of donor
mice with alloantigen and anti-CD4 antibodies led to the
generation of alloantigen-specific CD4
 
 
 
CD25
 
  
 
T cells that
could prevent the rejection of skin allografts. However, in
both studies only tolerized, but not untreated, CD4
 
 
 
CD25
 
  
 
T cells demonstrated an alloantigen-specific immu-
noregulatory activity that resulted in diminished GVHD
induction and allograft acceptance, respectively.
We have previously shown that NK T cells, another T
cell subpopulation with regulatory potential, suppress
GVHD in a murine model of allo-BMT across a complete
MHC class I and II barrier (38). Here, we used the same
model to investigate the capacity of CD4
 
 
 
CD25
 
  
 
T cells
to suppress or prevent aGVHD after allogeneic transplanta-
tion. The results clearly show that freshly isolated, unma-
nipulated CD4
 
 
 
CD25
 
  
 
T cells from the spleen or BM of
naive donor animals can suppress lethal GVHD induced by
coinjected CD4
 
 
 
CD25
 
  
 
T cells. We also demonstrate that
IL-10 production by transplanted CD4
 
 
 
CD25
 
  
 
T cells is
necessary for full protection. Finally, we provide evidence
that the CD4
 
 
 
CD25
 
  
 
T
 
reg 
 
cells had to be of donor origin
to convey protection from lethal GVHD.
 
Materials and Methods
 
Animals.
 
Male C57BL/6 (H-2K
 
b
 
) and BALB/c (H-2K
 
d
 
)
wild-type (WT) mice were obtained from the breeding facility of
the Department of Comparative Medicine (Stanford University
School of Medicine, Stanford, CA). Male B6.129P2-
 
Il10
 
tm1Cgn
 
(B6.IL-10
 
 
 
/
 
 
 
) mice were purchased from The Jackson Labora-
tory. All mice were 6–12-wk-old. The care of all experimental
animals was in accordance with institutional guidelines.
 
Antibodies and FACS
 
®
 
.
 
The following reagents were used for
flow cytometric analysis: unconjugated anti-CD16/32 (2.4G2),
allophycocyanin (APC)–anti-TCR
 
  
 
 (H57-597), FITC– and
PE–anti-CD4 (RM4-5), biotinylated anti-CD25 (7D4), PE–anti-
CD25 (PC61), FITC–anti-CD44 (IM7), FITC–anti-CD45RB
(16A), FITC–anti-CD62L (MEL-14), PE–anti-NK1.1 (PK136),
PE-anti–CTLA-4 (4F10), PE-hamster IgG (A19-3), and FITC-
anti–H-2K
 
b 
 
(AF6-88.5; all from BD Biosciences). Streptavidin–
Texas red conjugate was purchased from Caltag. All stainings
were performed in PBS/1% calf serum in the presence of purified
anti-CD16/32 at saturation to block unspecific staining via
FcRII/III. Propidium iodide was added before analysis to ex-
clude dead cells. All analyses were done on a modified dual laser
FACSVantage™ (Becton Dickinson) with FlowJo
 
® 
 
software
(Becton Dickinson) for data analysis. For intracellular staining of
CTLA-4, cells were stained for surface markers, washed twice,
fixed, and permeabilized using the cytofix/cytoperm kit from BD
Biosciences, and then stained with either PE-anti–CTLA-4 or
PE-hamster IgG as recommended in the kit manual.
 
Cell Isolation and Sorting.
 
Single cell suspensions were pre-
pared from spleens, washed twice, and filtered through a fine ni-
tex membrane. The samples were then enriched for either CD4
 
 
 
cells with anti-CD4 magnetic microbeads or CD25
 
  
 
cells with
PE–anti-CD25 Ab and anti-PE magnetic beads using the Midi-
MACS
 
® 
 
system (Miltenyi Biotec). After staining with anti-CD4
FITC and anti-CD25 PE as required, cells were FACS
 
® 
 
sorted
into CD4
 
 
 
CD25
 
  
 
and CD4
 
 
 
CD25
 
  
 
populations on a modified
dual laser FACSVantage™. For the preparation of purified BM
TCR
 
  
 
 
 
NK1.1
 
 
 
CD4
 
 
 
CD25
 
  
 
and TCR
 
  
 
 
 
NK1.1
 
 
 
CD4
 
 
 
CD25
 
  
 
cells, BM cells were obtained from the femur and tibia,
and single cell suspensions were prepared and filtered through
nitex. Cells were enriched for CD4
 
  
 
cells as described above.
Enriched cells were stained with APC–anti-TCR
 
  
 
, PE–anti-
NK1.1, FITC–anti-CD4, and biotin–anti-CD25 plus streptavi-
din–Texas red conjugate, and then FACS
 
® 
 
sorted on a modified
dual laser FACSVantage™. For the preparation of PB T cells,
PBMC were isolated from PB by density centrifugation on Lym-
pholyte M (Cedarlane Ltd.), washed twice in RPMI 1640 me-
dium (Bio Whittaker), and stained with PE–anti-CD4 and
APC–anti-TCR
 
  
 
. For the preparation of T cell–depleted
(TCD) BM, BM cells, obtained as described above, were stained
with biotin–anti-Thy1.2 (5a-8; Caltag) and streptavidin mag-
netic beads, and then passed over two consecutive MACS
 
®
 
LS separation columns (Miltenyi Biotec). TCD BM contained
 
 
 
0.01% T cells as determined by staining with APC–anti-
TCR
 
  
 
.
 
GVHD Model.
 
For BMT, BALB/c hosts were given total
body irradiation (TBI; 800 cGy) from a 200-Kv x-ray source and
injected with donor cells via the tail vein within 24 h. All mice
received 2 
 
  
 
10
 
6 
 
TCD BM cells for reconstitution with or with-
out T cells as indicated in the text and figures. Mice were kept on
antibiotic water (25 
 
 
 
g/ml neomycin/0.3 U/ml polymyxin B;
Sigma-Aldrich) for the first 28 d. The survival and appearance of
mice were monitored daily and body weight was measured
weekly. 100 d after transplantation, lineage-specific chimerism of
transplanted animals was measured by staining PBMC with
FITC-anti–H-2K
 
b 
 
and cell lineage markers, as listed above.
 
Histopathology.
 
Histopathological specimens from the skin,
liver, and large intestine were obtained on days 49 and 100 after
transplantation, fixed in formalin, and embedded into paraffin 
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blocks. Tissue sections were stained with hematoxylin and eosin,
and examined at 
 
 
 
400.
 
MLR and Polyclonal Stimulation Assays.
 
Cultures were set up
in triplicates in 96-well round-bottom plates (Costar) in a total
volume of 200 
 
 
 
l. Cells were cultured in RPMI 1640 medium
with 10% FCS, 10 mM Hepes, 1% nonessential amino acids, 2
mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin
(all from GIBCO BRL), and 5 
 
  
 
10 5 M 2-mercaptoethanol
(Sigma-Aldrich). Fixed numbers of responder cells and irradiated
allogeneic stimulator cells (105 cells, respectively) were mixed
with variable numbers of CD4 CD25  T cells to obtain the ra-
tios indicated in the text and figures. After lysis of red blood cells,
splenocytes were T cell depleted with anti-Thy1.2 magnetic
beads using the MidiMACS® system and irradiated with 3,000
cGy before they were used as stimulator cells. Proliferation was
assessed after 5 d by pulsing the cells with 1  Ci/well [3H]thymi-
dine (Amersham Biosciences) for the last 16 h. Cells were har-
vested onto filter membranes using a Wallac harvester (Perkin-
Elmer) and the amount of incorporated [3H]thymidine was
measured with a Wallac Betaplate counter (PerkinElmer).
The culture conditions for the suppression assays with polyclonal
anti-CD3 stimulation differed as follows: 5   104 TCD irradiated
splenocytes were incubated with 2.5    104 syngeneic FACS®-
sorted CD4 CD25  and/or 2.5   104 CD4 CD25  T cells in the
presence of 0.5  g/ml anti-CD3 (145-2C11; BD Biosciences). Pro-
liferation was measured as described above after 72 h of incubation.
Statistical Analysis. Differences in the survival of the groups of
hosts given BM transplants were analyzed using the log-rank test.
Differences in the proliferation of responder cells were analyzed
using the two-tailed Student’s t test.
Results
Freshly Isolated Splenic CD4 CD25  Treg Cells Suppress the
Proliferation of CD4 CD25  T Cells after Allogeneic Stimula-
tion In Vitro. Recently, several investigators have demon-
strated that purified, but otherwise nontreated, CD4 
CD25  T cells isolated from the PB of normal human vol-
unteers are able to suppress allospecific responses of CD4 
CD25  T cells in vitro in the MLR (27, 36). Similar results
were obtained in the murine system using a partially MHC
class II–mismatched strain combination (37). To show that
this also holds true in a situation of complete MHC class I
and II mismatch, we analyzed the ability of freshly isolated
C57BL/6 CD4 CD25  Treg cells (H-2b) to suppress the
proliferative response of syngeneic CD4 CD25  T cells in
vitro to allogeneic BALB/c (H-2d) stimulator cells. Highly
purified CD4 CD25  and CD4 CD25  T cells were pre-
pared from splenocytes in a two-step procedure combining
immunomagnetic beads for enrichment and flow cytome-
try for the separation and final purification of the CD25 
and CD25  subpopulations of CD4 T cells. Sorted popu-
lations routinely showed a purity of  96% on reanalysis
(Fig. 1 A).
105 sorted C57BL/6 CD4 CD25  T cells, cultured for
5 d with 105 irradiated TCD BALB/c splenocytes as stimula-
tors, showed a strong proliferative response (mean incorpo-
ration of 22,000   8,610 cpm; Fig. 1 B). This could be
suppressed in a dose-dependent way by the addition of in-
creasing numbers of C57BL/6 CD4 CD25  T cells to the
constant number of responder and stimulator cells in the
cultures, resulting in a  90% reduction of the response at a
CD25 :CD25  T cell ratio of 1:1 (mean 1,450    600
cpm, P   0.005; two-tailed Student’s t test) and a  50%
reduction (mean 8,200   1,300 cpm, P   0.03) at a 1:4 ra-
tio. In addition, sorted C57BL/6 CD4 CD25  T cells did
not proliferate in response to BALB/c stimulator cells.
When 105 CD4 CD25  T cells were added to the cultures
instead of CD4 CD25  T cells, no decrease in prolifera-
tion occurred (unpublished data). Thus, increasing the total
Figure 1. (A) Composition of the CD4  T cell population in the
spleen of an adult C57BL/6 mouse and purity of the FACS®-sorted
CD25  and CD25  subpopulations. (B) Dose-dependent suppression of
the alloresponses of C57BL/6 CD4 CD25  T cells to BALB/c stimulator
cells by C57BL/6 CD4 CD25  T cells. Cultures were set up with 105
sorted C57BL/6 CD4 CD25  T cells and 105 irradiated BALB/c stimu-
lator cells plus variable numbers of C57BL/6 CD4 CD25  T cells to ob-
tain the indicated ratios. The bars represent the means of triplicate values
and the brackets indicate the SDs. **, P   0.01; *, P   0.05 (Student’s t
test). One of two experiments with similar results is shown.392 Regulatory T Cells in Graft-Versus-Host Disease
number of cells in the cultures could not account for the
observed suppression. These results clearly demonstrate that
freshly isolated, untreated CD4 CD25  T cells are not
only hyporesponsive to a complete class I– and II–mis-
matched alloantigen, but are also able to suppress the allo-
response of cocultured CD4 CD25  T cells.
Splenic CD4 CD25  Treg Cells Suppress Lethal aGVHD
Induced by CD4 CD25  T Cells after Allogeneic Transplanta-
tion. aGVHD, induced by the transplantation of C57BL/
6-derived splenocytes into lethally irradiated BALB/c
hosts, is initiated predominantly by alloreactive CD4  do-
nor T cells (39). To see whether naive CD4 CD25  T
cells could suppress aGVHD induced by CD4 CD25  T
cells, we coinjected the two subpopulations at a 1:10 and
1:1 ratio with TCD BM into BALB/c hosts within 24 h
after lethal TBI (800 cGy; Fig. 2 A). All mice that received
4.5   105 CD4 CD25  T cells and TCD BM developed
signs of aGVHD (diarrhea, weight loss, and hunched pos-
ture) shortly after transplantation, and all died within 29 d.
Mice given only TCD BM cells appeared healthy and
100% of the animals survived for at least 100 d. At a
ratio of 1:10, which is similar to the percentage
of CD4 CD25  and CD4 CD25  T cells in the spleen of
normal C57BL/6 mice (Fig. 1 A), no protective effect of
the CD4 CD25  T cells could be seen. At a ratio of 1:1
of CD4 CD25  and CD4 CD25  T cells, however, the
recipients were clearly protected from lethal aGVHD and
93% survived for 100 d (P   0.0001; log-rank test). Ani-
mals receiving 9   105 CD4 CD25  T cells instead of the
mixture of 4.5    105  CD4 CD25   and 4.5    105
CD4 CD25  T cells, died even more quickly (by day 8
after transplant) than those receiving a single dose of 4.5  
105  CD4 CD25   T cells. Occasionally, recipients of
CD25  and CD25  T cells at a 1:1 ratio showed mild signs
of GVHD at  4–5 wk after transplantation and their mean
body weights during that time were lower than those of
the control group given TCD BM alone (Fig. 2 B). How-
ever, after 7–8 wk, the differences in mean body weights
between the two groups were no longer significant. In
contrast, the mean body weights of the animals given only
CD4 CD25  T cells dropped markedly within the first
1–3 wk after transplantation. We checked surviving ani-
mals that had been transplanted with CD4 CD25  and
CD4 CD25  T cells at a 1:1 ratio after 100 d for donor
cell chimerism of their PBMC. All animals showed com-
plete donor chimerism of B cells, macrophages, and granu-
locytes, and 11 out of 15 animals also displayed complete
chimerism of T cells, with the remaining recipients show-
ing  85% of donor-derived T cells (unpublished data).
We killed animals that had received TCD BM either alone
or with a 1:1 mixture of CD4 CD25  and CD4 CD25 
T cells at days 49 and 100 after allotransplantation for his-
topathological examination of GVHD target organs (large
intestine and skin). Although all tissues examined on day
100 were free of any signs of GVHD in both groups, T
cell recipients showed mild signs of GVHD in skin and gut
on day 49, including a mononuclear cell infiltrate in the
dermis, apoptotic intestinal crypt cells, and polymorpho-
nuclear and mononuclear cell infiltrates in the lamina pro-
pria (unpublished data).
CD4 CD25  Treg Cells Are Highly Enriched within the BM
T Cell Population. We previously showed that BM NK T
cells, another T cell subpopulation with regulatory poten-
tial, are potent suppressors of lethal GVHD (38). Although
NK T cells are rare among T cells in secondary lymphoid
organs such as the spleen, they are highly enriched within
BM T cells. Unseparated BM T cells are only very weak
inducers of GVHD and even after the removal of the NK
T cell subpopulation, the remaining CD4  BM T cells are
still not as potent in GVHD induction as their counterparts
from PB or spleen (39). This prompted us to look for
CD4 CD25  Treg cells in the BM of untreated C57BL/6
mice. Five-color FACS® analysis revealed that  30% of
Figure 2. (A) Lethal GVHD of BALB/c recipients induced by
C57BL/6 CD4 CD25  T cells can be suppressed by coinjected C57BL/6
CD4 CD25  T cells. BALB/c mice received 800 cGy TBI, 2   106
C57BL/6 TCD BM cells, and 4.5   105 C57BL/6 splenic CD4 CD25 
T cells (CD25 ) with variable numbers of C57BL/6 splenic
CD4 CD25  (CD25 ) or CD4 CD25  T cells (CD25 ) to obtain the
indicated ratios. Combined data from four independent experiments with
10–21 animals per group are shown. (B) Mean body weights and SDs of
BALB/c hosts (10 animals per group) after BMT. BALB/c mice received
800 cGy lethal TBI and either 2   106 C57BL/6 TCD BM cells alone
( ) or TCD BM plus 4.5   105 C57BL/6 CD4 CD25  T cells ( ), or
TCD BM plus a 1:1 mixture of 4.5   105 C57BL/6 CD4 CD25  and
4.5   105 CD4 CD25  T cells ( ).393 Hoffmann et al.
TCR    cells in the BM were CD4  and of these CD4 
T cells,  18% coexpressed NK1.1 (Fig. 3 A). None of the
latter cells expressed CD25 (unpublished data). However,
41% of the remaining NK1.1 CD4  T cell population ex-
pressed CD25. In comparison, CD4 TCR   NK1.1 
gated spleen cells contained only 13% CD25  cells. Addi-
tional analysis revealed that both CD4 CD25  T cells
from the BM and spleen shared the phenotype CD44int,
CD45RBlow, intracellular CTLA-4 , and bimodal expres-
sion of CD62L (Fig. 3 B).
To clarify whether CD4 CD25  T cells in BM are also
functionally comparable to CD4 CD25  Treg cells from
other lymphoid organs, we purified TCR   NK1.1 
CD4 CD25  cells from the BM of C57BL/6 animals and
examined their proliferative response to polyclonal acti-
vation via CD3 in the presence of autologous APC as
well as their suppressive potential toward CD4 CD25 
T cells from the spleen. As shown in Fig. 4 A, sorted
BM TCR   NK1.1 CD4 CD25  T cells did not pro-
liferate when stimulated via their TCR. In addition,
they suppressed the proliferation of cocultured splenic
CD4 CD25  T cells (32,700 vs. 5,150 cpm in the ab-
sence and presence of CD4 CD25  BM T cells, respec-
tively; P   0.001). When tested for their capacity to sup-
press the MLR using C57BL/6 responder T cells and
BALB/c stimulator cells,  98% suppression was observed
at a ratio of 1:1 of splenic responder to BM Treg cells
compared with cultures without BM Treg cells (Fig.
4 B). Thus, BM TCR   NK1.1 CD4 CD25  T cells
showed the typical behavior of CD4 CD25  Treg cells
from the spleen.
We determined whether BM CD4 CD25  T cells can
also suppress aGVHD after allogeneic transplantation. Le-
thally irradiated BALB/c hosts were transplanted with
C57BL/6 TCD BM cells and 105 CD4 CD25  T cells
from C57BL/6 PB with or without an equal number of
NK1.1 CD4 CD25  T cells from C57BL/6 BM. Our
previous studies showed that sorted BM TCR    T cells
(total T cells) can suppress GVHD induced by PB T cells
(38). As shown in Fig. 4 C, all animals that received TCD
BM alone survived without any signs of GVHD, whereas
88% of the animals that also received PB T cells died from
GVHD. In comparison, the survival of the group given PB
CD4 CD25  and BM CD4 CD25  T cells at a 1:1 ratio
was significantly increased with only 17% of the animals
dying during the observation period of 100 d (P   0.019).
Mice receiving CD4 CD25  instead of CD4 CD25  BM
T cells with PB T cells were not protected (71% of the an-
imals died; P   0.19). These results confirmed that BM
CD4 CD25  T cells are not only phenotypically, but also
Figure 3. Phenotypic characteriza-
tion of CD4 CD25 NK1.1  T cells
from C57BL/6 BM and spleen. (A)
Proportion of CD4 CD25 NK1.1 
cells among TCR     cells in
C57BL/6 BM (top) and spleen
(bottom). (B) Surface expression of
CD62L, CD44, and CD45RB, and
intracellular/surface expression of
CTLA-4 by CD4 CD25 NK1.1  T
cells in C57BL/6 BM (bold line) and
spleen (filled).394 Regulatory T Cells in Graft-Versus-Host Disease
functionally comparable to CD4 CD25  Treg cells from
the spleen.
CD4 CD25  Treg Cells from IL-10 /  Animals Suppress
the Proliferation of WT CD4 CD25  T Cells to Alloantigen In
Vitro, but Do Not Convey Full Protection from Lethal GVHD
In Vivo. Recently, it has been shown that IL-10 plays an
important role in the suppression of some experimental au-
toimmune diseases and the facilitation of tolerance to al-
loantigens in vivo by CD4 CD25  Treg cells (30, 31, 40).
However, this is in contrast to results obtained in vitro,
where attempts to block the suppression of CD25  by
CD25  T cells with anti–IL-4 or anti–IL-10 antibodies
have failed (22, 26–28). To further clarify the role of IL-10
production by Treg cells in the suppression of alloresponses
in vitro and in vivo, we first compared the capacity of
splenic CD4 CD25  Treg cells from WT and IL-10 / 
mice to suppress the proliferative response of WT splenic
CD4 CD25  T cells to alloantigen in vitro. As shown in
Fig. 5 A, the proliferation of CD4 CD25  T cells from
WT C57BL/6 animals in response to irradiated TCD
BALB/c splenocytes was suppressed in a comparable dose-
dependent way by both WT and IL-10–deficient Treg cells,
resulting in a  50% reduction in proliferation at a 1:4 ratio
of CD25  and CD25  T cells (P   0.05), and a  90% re-
duction (P   0.001) at a ratio of 1:1. These data clearly in-
Figure 4. Suppressive effect of NK1.1 CD4 CD25  T cells from the
BM of C57BL/6 mice. (A) Suppression of the proliferation of 2.5   104
C57BL/6 splenic CD4 CD25  T cells, stimulated with soluble anti–
CD3-Ab in the presence of autologous APC by 2.5   104 C57BL/6
NK1.1 CD4 CD25  T cells from BM, or CD4 CD25  T cells from the
spleen. The bars represent the means of triplicate values and the brackets
indicate the SDs. ***, P   0.001 (Student’s t test). One of two experi-
ments with similar results is shown. (B) Suppression of the alloresponse of
C57BL/6 CD4 CD25  T cells to BALB/c stimulator cells by C57BL/6
BM CD4 CD25  T cells. Cultures were set up with 105 sorted splenic
C57BL/6 CD4 CD25  T cells and 105 irradiated BALB/c stimulator
cells plus 105 C57BL/6 BM or splenic CD4 CD25  T cells. The bars
represent the means of triplicate values and the brackets indicate the SDs.
**, P   0.01 (Student’s t test). One of two similar experiments is shown.
(C) BALB/c recipients of C57BL/6 CD4 CD25  PB T cells can be
rescued from lethal aGVHD by the coinjection of C57BL/6
NK1.1 CD4 CD25 , but not NK1.1 CD4 CD25 , BM T cells.
BALB/c mice received 800 cGy TBI, 2   106 C57BL/6 TCD BM cells,
and 105 CD4 CD25  PB T cells with or without an equal number of
CD4 CD25 NK1.1  or CD4 CD25 NK1.1  BM T cells. Combined
data from two independent experiments with six to nine mice per group
are shown.
Figure 5. Functional comparison of CD4 CD25   T cells from
C57BL/6 WT and C57BL/6 IL-10 /  animals. (A) Dose-dependent
suppression of the alloresponses of C57BL/6 WT CD4 CD25  T cells to
BALB/c stimulator cells by C57BL/6 WT or IL-10 /  CD4 CD25  T
cells. Cultures were set up with 105 CD4 CD25  T cells, 105 BALB/c
stimulator cells, and variable numbers of CD4 CD25  Treg cells to obtain
the indicated ratios. The bars represent the means of triplicate values and
the brackets indicate the SDs. ***, P   0.001; *, P   0.05 (Student’s t
test). One of two experiments with similar results is shown. (B) Protec-
tion of BALB/c hosts from lethal aGVHD by CD4 CD25  T cells from
C57BL/6 WT and IL–10 /  animals. BALB/c mice received 800 cGy
TBI, 2   106 C57BL/6 TCD BM cells, and 4.5   105 C57BL/6 WT
CD4 CD25  T cells with or without 4.5   105 CD4 CD25  T cells
from either C57BL/6 WT- or IL-10–deficient mice. Combined data
from two independent experiments with 10 animals per group are shown.395 Hoffmann et al.
dicate that IL-10 production/secretion by Treg cells is not
involved in the direct suppression of alloreactivity in vitro.
We then explored the requirement for Treg cell–derived
IL-10 in the suppression of lethal GVHD by coinjecting
splenic CD4 CD25  T cells from C57BL/6 WT mice
with splenic CD4 CD25  T cells from IL-10 /  or WT
animals into lethally irradiated BALB/c hosts. Mice receiv-
ing additional IL-10–deficient Treg cells had a longer me-
dian survival time than those receiving WT CD4 CD25 
T cells alone (45 vs. 15 d, respectively; P   0.0001), but
60% of the mice eventually died within 60 d after trans-
plant. These latter mice never regained the baseline body
weight for animals receiving WT Treg cells as noted in Fig.
2 B, and continued to show clinical signs of GVHD, in-
cluding diarrhea. In contrast, mice that received additional
WT CD4 CD25  T cells were completely protected from
lethality (100% survival for  100 d) and returned to a nor-
mal appearance after mild and transient signs of aGVHD
(Fig. 5 B). These results demonstrate that protection from
lethal GVHD in vivo is partially dependent on IL-10 pro-
duction by donor CD4 CD25  Treg cells.
Responder-type, but Not Stimulator-type, Treg Cells Inhibit
Alloreactive CD25  T Cells In Vitro in MLR. It has been
shown that CD4 CD25  T cells need to be activated via
their T cell receptor to be functional in vitro, i.e., suppress
the response of CD4 CD25  or CD8  T cells to antigenic
or polyclonal stimuli (22, 23, 28). However, the nature of
antigens recognized by CD4 CD25  T cells and the pre-
requisites necessary for their activation, especially in the re-
sponse to alloantigens, are still only poorly understood. To
address this question we cocultured C57BL/6 splenic
CD4 CD25  T cells and irradiated BALB/c stimulator
cells in the presence of either C57BL/6 or BALB/c splenic
CD4 CD25  T cells at a 1:1 ratio. Whereas C57BL/6 Treg
cells suppressed the proliferation of the C57BL/6 CD4 
CD25   T cells by  95%, BALB/c-derived Treg  cells
slightly enhanced the proliferation of the CD4 CD25  T
cells (Fig. 6 A). A lack of suppression was also obtained
when C57BL/6 CD4 CD25  T cells were cocultured
with BALB/c CD4 CD25   T cells as responder and
C57BL/6 stimulator cells. Dieckmann et al. (41) obtained
comparable results with human allogeneic CD4 CD25 
and CD4 CD25  T cells, if the stimulator cells and the
CD4 CD25  T cells originated from the same donor.
Donor-type, but Not Host-type, Treg Cells Protect from Lethal
GVHD. In light of the in vitro data described above, we
determined whether Treg cells had to be of donor origin or
whether host-type Treg cells were capable of preventing
lethal GVHD. To answer this question, we isolated
CD4 CD25  T cells from the spleens of C57BL/6 mice
and coinjected them with either C57BL/6 or BALB/c
splenic CD4 CD25  T cells into lethally irradiated BALB/c
hosts. As expected, all animals receiving only C57BL/6
CD4 CD25  T cells developed severe GVHD and died by
day 23, whereas 100% of the animals receiving both
CD4 CD25  and CD4 CD25  T cells from C57BL/6
mice were protected from lethal GVHD and survived for
 100 d (P   0.0001; Fig. 6 B). In contrast, all recipients of
C57BL/6 CD4 CD25  T cells and BALB/c CD4 CD25 
T cells developed severe signs of GVHD and almost all
failed to regain their baseline body weight after the initial
decline. They continued to show clinical signs of GVHD,
including diarrhea, hunched back, and ruffled fur, and 90%
of the animals died of the disease within 78 d (Fig. 6 B).
Thus, survival of the latter group was not significantly dif-
ferent from the group given C57BL/6 CD4 CD25  T
cells alone (P   0.28). This clearly shows that transferred
host-type Treg cells may delay the onset of lethal GVHD,
but are ultimately unable to protect the recipients.
Discussion
Several recent studies have shown that human
CD4 CD25  T cells isolated from the PB, umbilical cord
blood, thymus, or tonsils of healthy volunteers can sup-
press alloresponses of conventional CD4  and CD8  T
Figure 6. (A) Comparison of the suppressive effects of responder- and
stimulator-type CD4 CD25  T cells on the alloresponses of BALB/c or
C57BL/6 CD4 CD25  T cells in the MLR. Cultures were set up with
105 CD4 CD25  responder T cells and equal numbers of each of the re-
maining cell populations. The bars represent the means of triplicate values
and the brackets indicate the SDs. **, P   0.01 (Student’s t test). One of
two experiments with similar results is shown. (B) Comparison of the
protective effect of CD4 CD25  T cells from C57BL/6 and BALB/c
animals in lethal aGVHD of BALB/c hosts induced by C57BL/6
CD4 CD25  T cells. BALB/c mice received 800 cGy TBI, 2   106
C57BL/6 TCD BM cells, and 4.5   105 C57BL/6 CD4 CD25  T cells
with or without 4.5   105 CD4 CD25  T cells from either C57BL/6 or
BALB/c animals. Combined data from two independent experiments
with 10 animals per group are shown.396 Regulatory T Cells in Graft-Versus-Host Disease
cells in vitro (16, 29, 42). In the current murine study,
CD4 CD25  T cells from the spleen of C57BL/6 mice
showed significant suppression of the MLR of CD4 
CD25  T cells toward BALB/c stimulator cells, even at a
ratio of 1:4 of CD25 /CD25  cells. Other reports demon-
strated that the induction of tolerance to alloantigen in
vivo, either in neonatal mice by the injection of semi-
allogeneic spleen cells within 24 h after birth (43), or
in adult mice by the treatment with anti-CD4 Ab fol-
lowed by the injection of allogeneic blood (31), depends
on the presence of CD4 CD25  T cells. Furthermore,
CD4 CD25  T cells isolated from mice tolerized by either
treatment displayed a strong, alloantigen-specific suppres-
sive activity, as shown in vitro and by long-term accep-
tance of allografts in vivo. In both cases, however,
CD4 CD25   T cells isolated from unprimed animals
showed no alloantigen-specific regulatory function either
in vitro or in vivo. Taylor et al. (37) recently reported that
the induction of tolerance to alloantigens ex vivo by the
costimulatory blockade of either the CD40/CD40L or the
CD28/CTLA-4/B7 pathway also depends on the presence
of CD4 CD25   T cells. Whole CD4   cells, but not
CD4 CD25  cells, cultured under blocking conditions for
9 d in vitro had a reduced capacity to induce lethal GVHD
in a C57BL/6→B6.C-H2bm12/KhEg transplantation
model. However, freshly isolated CD4 CD25  T cells,
when injected with an equal number of naive, unseparated
CD4  T cells, only marginally prolonged the survival time
of the recipients compared with animals transplanted with
only CD4  cells without any rescue from lethal GVHD.
This is in contrast to our current findings in the murine
C57BL/6→BALB/c transplantation model that shows sig-
nificant protection from GVHD lethality by unmanipu-
lated donor-type CD4 CD25  T cells. We were able to
rescue  90% of BALB/c recipients given a high dose of
4.5   105 sorted C57BL/6-derived CD4 CD25  T cells
from lethal GVHD by coinjecting the animals with an
equal number of freshly isolated CD4 CD25  T cells from
the C57BL/6 donors. This is particularly striking, as we
have shown that as few as 0.25   105 CD4  T cells, trans-
planted with 1.5    106 TCD BM cells, caused severe
GVHD and the death of half of the animals within 70 d
(39). There are, however, several differences between the
experimental GVHD models applied by Taylor et al. (37)
and by us, such as differences in the preparatory regimen
(sublethal vs. lethal irradiation), in strain disparity (partial
mismatch in MHC class II vs. complete MHC class I and
II mismatch), and in the numbers and phenotype of the
transplanted cells that could very well account for the dif-
ferent outcome of the experiments.
After allogeneic transplantation, aGVHD is characterized
by donor leukocyte infiltrates in the gut and liver (39). Re-
cruitment, activation, and expansion of mature donor T
cells at these sites is regarded as one of the key processes
during the initiation phase of GVHD that can lead to se-
vere tissue damage, multiorgan failure, and death of the
transplanted hosts (3). Using FACS® analysis and immuno-
histochemistry, we have demonstrated the presence of both
CD4 CD25   T cells and CD4 CD25   donor T cells
(and/or their progeny) in GVHD target tissues (gut and
liver) 5 d after cotransfer into lethally irradiated hosts (un-
published data). This indicates that CD4 CD25  T cells do
not prevent CD4 CD25  T cells from entering GVHD
target organs, but rather comigrate and then restrict the lo-
cal expansion and/or tissue-damaging proinflammatory ac-
tivity of the CD4 CD25  T cells at these sites. This inter-
pretation is supported by two studies showing that
CD4 CD25  T cells regulate the expansion of CD4 
CD25  T cells after cotransfer into lymphocyte-deficient
mice (40) and, although proliferating to a certain degree af-
ter transfer, CD4 CD25  T cells do so without loss of
their suppressive function (44).
Because CD4 CD25  T cells suppress GVHD, it is im-
portant to determine whether they also suppress the graft-
versus-tumor activity of cotransplanted T cells that is desir-
able after clinical, allogeneic BMT. Accordingly, we
recently performed a separate study in which C57BL/6
CD4 CD25  T cells were used to suppress GVHD in
BALB/c hosts bearing the BALB/c-derived B cell lym-
phoma, BCL1 (unpublished data). All hosts given C57BL/6
TCD BM cells alone died from progressive tumor growth,
whereas hosts given donor TCD BM cells with donor
CD4  and CD8  T cells all died early from aGVHD. In
contrast, all animals given the latter donor cells along with
donor Treg cells survived without tumor growth or GVHD.
In this model, tumor eradication has been previously
shown to be mediated by donor CD8  T cells via the per-
forin and FasL pathways (45).
We have previously shown that NK T cells, another T
cell subpopulation with regulatory potential that is charac-
terized by the coexpression of NK and T cell markers, can
prevent lethal GVHD in the C57BL/6→BALB/c trans-
plantation model (38). Although very rare among T cells in
the periphery (2–5% of T cells in the spleen), these cells are
highly enriched within the BM T cell population, where
they represent 25–30% of the TCR    cells (38). Al-
though a high dose of BM T cells failed to induce GVHD
in mice, we could induce GVHD after removal of the
NK1.1  T cell subpopulation (38). However, the NK1.1 
T cells isolated from PB were far more potent in inducing
lethal GVHD compared with equal numbers from the BM.
The results presented here, showing that up to 40% of the
NK1.1 CD4  T cells within the BM of C57BL/6 mice
actually belong to the CD25  Treg cell pool, as judged from
their phenotype as well as their functional activity in vitro
and in vivo, could explain the poor capacity of BM CD4 /
CD8 NK1.1  T cells to induce GVHD and the even lesser
ability of purified BM CD4 NK1.1  T cells (38, 39). The
absolute number, however, of CD4 CD25  T cells in the
spleen is still five- to eightfold higher than that in the BM
based on the percentage among nucleated cells in these or-
gans and the estimated total number of 3.2   108 nucleated
cells in the BM of adult mice (46).
It has clearly been shown in the murine as well as the
human system that the suppressive effect of CD4 CD25 
T cells on cocultured CD4 CD25  T cells in vitro requires397 Hoffmann et al.
cell contact and does not involve soluble mediators (22,
27–29, 36). In contrast, there are several studies document-
ing a role for IL-10 and TGF-  in the regulatory function
of CD4 CD25  T cells in vivo (31, 32, 40, 47). We did
not determine in this study whether WT Treg cells secreted
IL-10 in vitro when stimulated by alloantigen. However,
using CD4 CD25  T cells from IL-10 /  mice, we were
unable to detect any dependency of the suppressive effect
of these cells on alloreactive CD4 CD25  T cells in vitro,
which is in agreement with previous reports (27, 29).
When transferred into lethally irradiated hosts with WT
CD4 CD25  T cells, however, CD4 CD25  Treg  cells
from IL-10 /  mice conveyed a significantly reduced pro-
tection from GVHD compared with that found after the
transfer of WT CD4 CD25  Treg cells. Although the MLR
only measures the proliferative response of the target
CD4 CD25  T cells and its immediate suppression, the
GVHD assay measures a complex series of downstream im-
mune events that culminate in tissue injury. It is possible
that CD4 CD25  Treg cells, in addition to their direct sup-
pressive effect, transform the target T cells via IL-10 into
Treg cells that could then inhibit these downstream immune
events. This form of “infectious tolerance” has been re-
ported in several other systems (48, 49). Thus, the cell con-
tact–dependent mechanism of suppression measured in
vitro may just be the earliest of a cascade of events triggered
by Treg cells in vivo.
When we studied the suppression of proliferation after
polyclonal T cell stimulation in vitro, we found full coop-
eration between CD4 CD25  T cells from C57BL/6 and
CD4 CD25  T cells from BALB/c animals, and vice versa,
resulting in the complete suppression of the proliferative
response. However, when we cultured MHC mismatched
CD4 CD25  and CD4 CD25  T cells in the presence of
APC from the same mouse strain as the CD4 CD25  T
cells, no suppression of the proliferative response occurred.
Similarly, host-type CD4 CD25  T cells were unable to
protect recipients from lethal GVHD induced by allogeneic
CD4 CD25  T cells. All three findings are in accordance
with the notion that Treg cells have to be stimulated via
their T cell receptor to be fully functional but once acti-
vated, their suppressive effect is antigen nonspecific, i.e.,
donor regulatory cells require activation via allorecognition
of stimulator or host cells to suppress (22, 36, 50).
In conclusion, we have demonstrated that freshly iso-
lated CD4 CD25  T cells from unprimed animals can
rescue recipients from lethal GVHD induced by CD4 
CD25  T cells after allogeneic transplantation. In addition,
our findings indicate that protection from lethality is par-
tially dependent on IL-10 produced by transplanted
CD4 CD25  T cells and that only donor-type CD4 
CD25  T cells are capable of preventing the death of the
host animals.
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